San francisco: Dark Horse Consulting Group (DHCG), a leader in strategic and operational biotherapeutics consulting, has announced the acquisition of Bruder Consulting and Venture Group (BCVG). BCVG, renowned for its expertise in the discovery, development, clinical design, and regulatory approval process of biologics, devices, and combination products, will now operate as a department within DHCG, known as DHC Regenerative Medicine.

According to BERNAMA News Agency, this acquisition strengthens DHCG's commitment to advancing the development and commercialization of biotherapeutics. The integration of BCVG enhances DHCG's consulting services by expanding its capabilities to include regenerative medicine, tissue repair, and biomaterials. This move is part of DHCG's strategy to build an integrated ecosystem of consulting services, complementing recent expansions with BioTechLogic and Converge Consulting. BCVG's global reach aligns with DHCG's objective to function as a fully integrated global consulting practice.